To date, 110 patients have been enrolled in the CALVID-1 trial, and a total of 230 patients are expected to be enrolled in 10-35 centers across Europe and the U.S. During the interim safety analysis of the trial, an independent data monitoring committee concluded that the study should continue without changes. While the safety evaluation was conducted on a relatively small number of patients, it marks an important milestone in the clinical development of IMU-383.

The company plans to report more results once approximately 200 patients have been treated and if a subsequent phase III trial is warranted.

Immunic begins phase II trial of COVID-19 immunotherapy
Immunic has enrolled the first patients in a phase II clinical trial of IMU-838, a selective oral dihydroorotate dehydrogenase inhibitor, in combination...

Immunic begins phase II immunotherapy for COVID-19
Immunic has enrolled the first COVID-19 patients in a phase II clinical trial of IMU-838, a selective oral dihydroorotate dehydrogenase (DHODH) inhibitor.